EPITHELIAL OVARIAN CANCER
Clinical trials for EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on ovarian cancer in early trial
Disease control OngoingThis early-stage trial tests a new treatment for women whose ovarian cancer has come back. The therapy uses the patient's own immune cells, modified to target a protein called B7-H3 on cancer cells. The main goal is to find a safe dose and check for side effects in up to 21 parti…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
New gene therapy shows promise in fight against ovarian cancer
Disease control OngoingThis study tests a new treatment called IMNN-001, a gene therapy that boosts the immune system, given together with standard chemotherapy for people newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps ke…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Imunon • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Heated chemo during surgery may extend life in resistant ovarian cancer
Disease control OngoingThis study tests whether adding surgery and heated chemotherapy (HIPEC) to standard care helps women with platinum-resistant ovarian cancer live longer without the disease getting worse. About 140 participants will be randomly assigned to receive either surgery plus HIPEC or stan…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE3 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New hope for tough cancers: SKB264 trial targets tumors resistant to standard care
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not improved with standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 1,410 participants will receive the drug…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC